Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gniadecki

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|December 18, 2020
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence studyJ F B Schwensen, V W Nielsen, C V Nissen, et al.
The British Journal of Dermatology|August 3, 2006
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinionC Assaf, M Bagot, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2007
Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?R Dummer, C Assaf, M Bagot, et al.
The British Journal of Dermatology|June 8, 2007
The optimal use of bexarotene in cutaneous T-cell lymphomaR Gniadecki, C Assaf, M Bagot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 1, 2011
Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimensR Gniadecki, D Robertson, C T Molta, et al.
The British Journal of Dermatology|October 5, 2011
Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II studyM R Kamstrup, L M Lindahl, R Gniadecki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Clinical and Experimental Dermatology|October 23, 2012
Ultraviolet A1 phototherapy for mycosis fungoidesK Olek-Hrab, W Silny, A Dańczak-Pazdrowska, et al.
Dermatologic Therapy|September 15, 2017
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter studyJ F Schwensen, A Clemmensen, C Sand, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2023
An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasisK Eyerich, J Krueger, M Stahle, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|December 18, 2020
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence studyJ F B Schwensen, V W Nielsen, C V Nissen, et al.
The British Journal of Dermatology|August 3, 2006
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinionC Assaf, M Bagot, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2007
Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?R Dummer, C Assaf, M Bagot, et al.
The British Journal of Dermatology|June 8, 2007
The optimal use of bexarotene in cutaneous T-cell lymphomaR Gniadecki, C Assaf, M Bagot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 1, 2011
Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimensR Gniadecki, D Robertson, C T Molta, et al.
The British Journal of Dermatology|October 5, 2011
Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II studyM R Kamstrup, L M Lindahl, R Gniadecki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Clinical and Experimental Dermatology|October 23, 2012
Ultraviolet A1 phototherapy for mycosis fungoidesK Olek-Hrab, W Silny, A Dańczak-Pazdrowska, et al.
Dermatologic Therapy|September 15, 2017
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter studyJ F Schwensen, A Clemmensen, C Sand, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2023
An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasisK Eyerich, J Krueger, M Stahle, et al.
Pageof 10